Evaxion A (EVAX) Non-Current Debt (2021 - 2025)
Evaxion A (EVAX) reported Non-Current Debt of $5.3 million for Q4 2025, down 33.23% on a YoY basis from $8.0 million in Q4 2024, and down 40.79% quarter-over-quarter from $9.0 million in Q2 2025.
Evaxion A (EVAX) Non-Current Debt (2021 - 2025) Analysis & Trends
Evaxion A has reported Non-Current Debt for 5 years, with the latest figure at $5.3 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Debt fell 33.23% year-over-year to $5.3 million; the trailing twelve-month figure through Dec 2025 stood at $5.3 million (down 33.23% YoY), and the FY2025 full-year result was $5.3 million, down 33.23% from the prior year.
- Non-Current Debt for Q4 2025 stood at $5.3 million, down from $9.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $9.0 million in Q2 2025, with the low at $1.0 million in Q4 2021.
- Historically, Non-Current Debt has averaged $6.6 million across 5 years, with a median of $7.9 million in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Debt surged 653.26% — and 2025, when it slumped 33.23%.
- Evaxion A's Non-Current Debt stood at $1.0 million in 2021, then surged by 653.26% to $7.9 million in 2022, then advanced by 7.95% to $8.5 million in 2023, then decreased by 5.67% to $8.0 million in 2024, then tumbled by 33.23% to $5.3 million in 2025.
- The last three Non-Current Debt figures came in at $5.3 million (Q4 2025), $9.0 million (Q2 2025), and $8.0 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 1.99 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.35 Mn |
| Dec 31, 2025 | 5.35 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Dec 31, 2024 | 8.01 Mn |
| Dec 31, 2024 | 8.01 Mn |
| Jun 30, 2024 | 8.26 Mn |
| Jun 30, 2024 | 8.26 Mn |
| Dec 31, 2023 | 8.49 Mn |
| Dec 31, 2023 | 8.49 Mn |
| Jun 30, 2023 | 8.08 Mn |
| Jun 30, 2023 | 8.08 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Jun 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | 7.34 Mn |
| Mar 31, 2022 | 7.72 Mn |
| Mar 31, 2022 | 7.72 Mn |
| Dec 31, 2021 | 1.04 Mn |
| Dec 31, 2021 | 1.04 Mn |